# Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

> **NCT07328022** · PHASE3 · COMPLETED · sponsor: **Laboratorios Silanes S.A. de C.V.** · enrollment: 89 (actual)

## Conditions studied

- Bursitis
- Tendinitis
- Synovitis

## Interventions

- **DRUG:** Fixed Dose Etoricoxib + Betamethasone
- **DRUG:** Monotherapy Etoricoxib

## Key facts

- **NCT ID:** NCT07328022
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-14
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-11-19
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328022, "Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07328022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*